Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment
August 21, 2023Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia
Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …
FDA approves first ever treatment for rare CHAPLE disease
August 21, 2023Research and Development CHAPLE disease, FDA, Rare Diseases, rare disease
The US Food and Drug Administration (FDA) has approved Regeneron’s Veopoz (pozelimab), a new treatment for CHAPLE disease for both …
Destiny Pharma appoints new CEO Chris Tovey
August 21, 2023Business Services CEO, Chris Tovey, Destiny Pharma, Infections and infestations
Destiny Pharma has announced the appointment of Chris Tovey, who will be replacing Dr Debra Barker as chief executive officer; …
FDA approves IMIDEX’s AI-powered device VisiRad XR
August 18, 2023Research and Development FDA, Radiology, pharma, radiology
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug Administration (FDA) for its artificial …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA
August 18, 2023Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …
Dr Michael Lutz appointed as new chief executive officer of iotaSciences
August 18, 2023Business Services Dr Michael Lutz, Haematology, chief executive officer, iotasciences
The pharmaceutical discovery company iotaSciences has announced that it has appointed Dr Michael Lutz as its new chief executive officer. …
Foghorn Therapeutics appoints Alfonso Quintás-Cardama as new chief medical officer
August 18, 2023Business Services Alfonso Quintas-Cardama, Foghorn Therapeutics, Haematology, chief medical officer
The biotechnology company Foghorn Therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be …
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva
August 17, 2023Medical Communications FDA, FOP, Musculo-skeletal disorder, Sohonos, ipsen
Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules as a retinoid indicated …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
August 17, 2023Research and Development FDA, IND, Immunology, lupus nephritis, pharma
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ Investigational New Drug (IND) application …
Sandoz shares positive results from MYLIGHT phase 3 study
August 16, 2023Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration
Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …
Tempus receives FDA Breakthrough Device Designation for its companion diagnostic test
August 16, 2023Research and Development Diagnostics, FDA, Tempus, breakthrough device designation, diagnostic
Tempus has announced that the US Food and Drug Administration (FDA) has granted it Breakthrough Device Designation for its HLA-LOH …
FDA grants accelerated approval to Pfizer’s Elrexfio
August 15, 2023Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval
Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …
FDA grants orphan drug designation to Genprex’s Reqorsa
August 15, 2023Medical Communications FDA, ODD, Oncology, Reqorsa
Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …
NICE shares draft guidance for AI’s use in radiotherapy treatment planning
August 14, 2023Research and Development AI, Draft Guidance, NICE, Oncology, radiotherapy
The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine artificial intelligence (AI) technologies which …
FDA approved Janssen’s Akeega for prostate cancer treatment
August 14, 2023Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer
The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
Zumutor’s cancer drug trial cleared by FDA
August 14, 2023Research and Development Cancer, Oncology, clinical trial, pharmaceutical
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its ZM008 drug for cancer had …
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
Regeneron shares two-year PULSAR trial results for wAMD
August 11, 2023Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD
Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …
Latest content
FibroFind appoints Lee Borthwick as CEO
